Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials

Respiratory Medicine

Volumn 109, Issue 1, 2015, Pages 105-111

  Wedzicha, Jadwiga A ^a   Buhl, Roland ^b   Lawrence, David ^c   Young, David ^d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Bronchodilator; COPD; Exacerbations; Indacaterol; Pooled analysis; 2 agonist

Indexed keywords

INDACATEROL; PLACEBO; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; FORCED EXPIRATORY VOLUME; KAPLAN MEIER METHOD; META ANALYSIS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; KAPLAN-MEIER ESTIMATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84919775418     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.10.011     Document Type: Article

References (30)

1. S. Spencer, P.M.A. Calverley, P.S. Burge, and P.W. Jones Impact of preventing exacerbations on deterioration of health status in COPD Eur Respir J 23 2004 698 702
2. D.M. Halpin, M. Decramer, B. Celli, S. Kesten, D. Liu, and D.P. Tashkin Exacerbation frequency and course of COPD Int J Chron Obstruct Pulmon Dis 7 2012 653 661
3. J. Soler-Cataluna, M. Martinez-Garcia, S. Roman, E. Salcedo, M. Navarro, and R. Ochando Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60 2005 925 931
4. K.M. Beeh, T. Glaab, S. Stowasser, H. Schmidt, L.M. Fabbri, K.F. Rabe, and C.F. Vogelmeier Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial Respir Res 14 2013 116
5. J.A. Wedzicha, and T.A. Seemungal COPD exacerbations: defining their cause and prevention Lancet 370 2007 786 796
6. F. Andersson, S. Borg, S.-A. Jansson, A.C. Jonsson, A. Ericsson, C. Prutz, E. Ronmark, and B. Lundback The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med 96 2002 700 708
7. E.L. Toy, K.F. Gallagher, E.L. Stanley, A.R. Swensen, and M.S. Duh The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review COPD 7 2010 214 228
8. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2013 Available from: www.goldcopd.org/uploads/users/files/GOLD-Report-2013-Feb19.pdf [accessed: 22.08.13]
9. M. Cazzola, M.G. Matera, and J. Lotvall Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease Expert Opin Investig Drugs 14 2005 775 783
10. R. Dahl, K.F. Chung, R. Buhl, H. Magnussen, V. Nonikov, D. Jack, P. Bleasdale, R. Owen, M. Higgins, and B. Kramer Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
11. J.F. Donohue, C. Fogarty, J. Lötvall, D.A. Mahler, H. Worth, A. Yorgancioglu, A. Iqbal, J. Swales, R. Owen, M. Higgins, B. Kramer, and INHANCE Study Investigators Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
12. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, C. Lassen, and B. Kramer Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2011 273 279
13. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2005
14. J.R. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Müllerova, R. Tal-Singer, B. Miller, D.A. Lomas, A. Agusti, W. Macnee, P. Calverley, S. Rennard, E.F. Wouters, J.A. Wedzicha, and Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 2010 1128 1138
15. J.A. Wedzicha, M. Decramer, and T.A.R. Seemungal The role of bronchodilator treatment in the prevention of exacerbations of COPD Eur Respir J 40 2012 1545 1554
16. B. Celli, R. ZuWallack, S. Wang, and S. Kesten Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes Chest 124 2003 1743 1748
17. R. Rodriguez-Roisin Impacting patient-centred outcomes in COPD: exacerbations and hospitalizations Eur Respir Rev 15 2006 47 50
18. M. Trevethick, N. Clarke, M. Strawbridge, and M. Yeadon Inhaled muscarinic antagonists for COPD-does an anti-inflammatory mechanism really play a role? Curr Opin Pharmacol 9 2009 250 521
19. M. Thomas, M. Decramer, and D.E. O'Donnell No room to breathe: the importance of lung hyperinflation in COPD Prim Care Respir J 22 2013 101 111
20. D.E. O'Donnell Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease Proc Am Thorac Soc 3 2006 180 184
21. M. Johnson, and S. Rennard Alternative mechanisms for long-acting b2-adrenergic agonists in COPD Chest 120 2001 258 270
22. M. Profita, A. Bonanno, A.M. Montalbano, G.D. Albano, L. Riccobono, L. Siena, M. Ferraro, P. Casarosa, M.P. Pieper, and M. Gjomarkaj β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD Biochim Biophys Acta 1822 2012 1079 1089
23. J.A. Wedzicha, P.M. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari, R.A. Stockley, and INSPIRE Investigators The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care. Med 177 2008 19 26
24. R.A. Stockley, N. Chopra, and L. Rice Addition of salmeterol to existing treatment in patients with COPD: a 12 month study Thorax 61 2006 122 128
25. D. Dusser, M.-L. Bravo, and P. Iacono The effect of tiotropium on exacerbations and airflow in patients with COPD Eur Respir J 27 2006 547 555
26. C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P. Rutten-van Mölken, K.M. Beeh, K.F. Rabe, L.M. Fabbri, and POET-COPD Investigators Tiotropium versus salmeterol for the prevention of exacerbations of COPD N Engl J Med 364 2011 1093 1103
27. S. Suissa, V. Patenaude, F. Lapi, and P. Ernst Inhaled corticosteroids in COPD and the risk of serious pneumonia Thorax 68 2013 1029 1036
28. S. Suissa Number needed to treat in COPD: exacerbations versus pneumonias Thorax 68 2013 540 543
29. Cates Inhaled corticosteroids in COPD: quantifying risks and benefits Thorax 68 2013 499 500
30. H. Worth, K.F. Chung, J.M. Felser, H. Hu, and P. Ruegg Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD Respir Med 105 2011 571 579